Dechra Pharmaceuticals ROA 2024

Dechra Pharmaceuticals Aktienanalyse

What does Dechra Pharmaceuticals do?

Dechra Pharmaceuticals PLC is a British company specializing in animal medicine. It was founded in 1997 and has experienced remarkable growth since then. Dechra is listed on the London Stock Exchange and has its headquarters in Northwich, Cheshire, UK. Dechra builds its business models on a broad portfolio of products and services. The company is primarily focused on the development and sale of pharmaceuticals and diagnostics tailored to the needs of veterinarians and pet owners. The company has an extensive range of animal medicines, divided into categories such as antibiotics, painkillers, and anti-inflammatory drugs. Dechra operates three major business segments that drive its growth: the veterinary medicines business, the diagnostics business, and the specialty pharma business. The veterinary medicines business is the core of Dechra's operations. Here, the company produces products that can be used on livestock and companion animals. Dechra dominates the animal medicine market in Europe and has also established itself in the field of animal health in the US. The diagnostics business is another important segment that focuses on diagnostics and tests to quickly and effectively diagnose animal diseases. These products are primarily sold to veterinarians and veterinary laboratories. Dechra's specialty pharma business focuses on the production of specialty drugs tailored to a specific animal species or a specific disease that affects rarer species. Producing such medications generally requires higher expertise and also results in higher profitability due to typically lower competition. In recent years, Dechra has accelerated its presence and growth through targeted acquisitions. These acquisitions have expanded both Dechra's portfolio and geographic reach. In 2014, Dechra acquired US-based Genera N.A., a specialized pharmaceutical company producing animal medicines. With the acquisition of Genera, Dechra was able to strengthen its presence in the US animal medicine market. The company has also made acquisitions in Europe, such as the acquisition of Eurovet Animal Health in 2020. Eurovet is a Netherlands-based company specializing in animal health products and covers important market regions in Europe. The acquisition of Eurovet has allowed Dechra to strengthen its presence in Germany and Scandinavia. In summary, Dechra Pharmaceuticals PLC is one of the leading companies in the animal medicine industry. The company has maintained its reputation by creating innovative products and services based on the highest manufacturing and operational standards. The company is committed to continuing to provide value to veterinarians and pet owners while improving the health and well-being of animals. Dechra Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Dechra Pharmaceuticals's Return on Assets (ROA)

Dechra Pharmaceuticals's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Dechra Pharmaceuticals's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Dechra Pharmaceuticals's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Dechra Pharmaceuticals’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Dechra Pharmaceuticals stock

What is the Return on Assets (ROA) of Dechra Pharmaceuticals this year?

The Return on Assets (ROA) of Dechra Pharmaceuticals is -0.02 undefined this year.

What was the ROA of Dechra Pharmaceuticals compared to the previous year?

The ROA of Dechra Pharmaceuticals has increased by -139.5% compared to the previous year.

What consequences do high ROA have for investors of Dechra Pharmaceuticals?

A high ROA is advantageous for investors of Dechra Pharmaceuticals, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Dechra Pharmaceuticals?

A low ROA can be unfavorable for investors of Dechra Pharmaceuticals as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Dechra Pharmaceuticals affect the company?

An increase in ROA of Dechra Pharmaceuticals can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Dechra Pharmaceuticals impact the company?

A reduction in the ROA of Dechra Pharmaceuticals can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Dechra Pharmaceuticals?

Some factors that can influence the ROA of Dechra Pharmaceuticals include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Dechra Pharmaceuticals important for investors?

The ROA of Dechra Pharmaceuticals is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Dechra Pharmaceuticals take to improve ROA?

To improve ROA, Dechra Pharmaceuticals can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Dechra Pharmaceuticals pay?

Over the past 12 months, Dechra Pharmaceuticals paid a dividend of 0.25 GBP . This corresponds to a dividend yield of about 0.65 %. For the coming 12 months, Dechra Pharmaceuticals is expected to pay a dividend of 0.25 GBP.

What is the dividend yield of Dechra Pharmaceuticals?

The current dividend yield of Dechra Pharmaceuticals is 0.65 %.

When does Dechra Pharmaceuticals pay dividends?

Dechra Pharmaceuticals pays a quarterly dividend. This is distributed in the months of November, April, November, April.

How secure is the dividend of Dechra Pharmaceuticals?

Dechra Pharmaceuticals paid dividends every year for the past 25 years.

What is the dividend of Dechra Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0.25 GBP are expected. This corresponds to a dividend yield of 0.65 %.

In which sector is Dechra Pharmaceuticals located?

Dechra Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Dechra Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Dechra Pharmaceuticals from 4/13/2023 amounting to 0.125 GBP, you needed to have the stock in your portfolio before the ex-date on 3/9/2023.

When did Dechra Pharmaceuticals pay the last dividend?

The last dividend was paid out on 4/13/2023.

What was the dividend of Dechra Pharmaceuticals in the year 2023?

In the year 2023, Dechra Pharmaceuticals distributed 0.449 GBP as dividends.

In which currency does Dechra Pharmaceuticals pay out the dividend?

The dividends of Dechra Pharmaceuticals are distributed in GBP.